Verismo Therapeutics, a Philadelphia-based clinical-stage CAR T cell therapy company, has licensed a technology from Stanford Medicine that could let it engineer cancer-fighting immune cells inside a patient’s body rather than in a manufacturing facility, the company announced on November 18, 2026. Verismo plans to apply the technology, called PACK-IT, to its KIR-CAR platform.
“Today, KIR-CAR is advancing along the established CAR T pathway in two Phase 1 clinical trials, and adding the PACK-IT technology is intended to extend the platform into next-generation, off-the-shelf in vivo delivery — realizing the full potential of KIR-CAR to reach more patients, faster, and at lower cost,” said Bryan Kim, CEO and Co-Founder of Verismo Therapeutics.
Why Making CAR T Cells Inside the Body Matters
Approved CAR T therapies are made outside the body, a process called ex vivo. A patient’s immune cells are collected, engineered, grown, and tested over several weeks before being returned. The approach works, but its complexity adds cost and limits how many patients can get treated.
PACK-IT, short for Programmable Antigen-Mediated Cellular Knock-in of T cell, uses engineered viral particles that target T cells and deliver CAR genes directly. It can be used either inside the body or in a faster version of the standard outside-the-body process. Verismo plans to use it mainly for off-the-shelf, in-body treatment, which the company says could turn a multi-week manufacturing process into a same-day step.
The technology comes from the lab of Dr. Crystal Mackall, the Ernest and Amelia Gallo Family Professor and professor of pediatrics and medicine at Stanford Medicine, and founding director of the Stanford Center for Cancer Cell Therapy. In preclinical research presented at the American Association for Cancer Research (AACR) 2025 Annual Meeting, PACK-IT produced CAR T cells with greater potency than conventional methods and generated CD19-targeting CAR T cells inside the body that controlled leukemia in animal models.
Verismo’s KIR-CAR Platform
Verismo’s platform differs from standard CAR T therapy in its design. Conventional CAR T uses a single-chain receptor. KIR-CAR uses a multi-chain approach built from killer immunoglobulin-like receptors (KIR) and DAP12, both found on natural killer cells. That design splits the signals for finding a tumor and activating the T cell, which Verismo says is intended to keep T cells working longer and avoid the exhaustion seen with conventional CAR T.
Two KIR-CAR candidates are in Phase 1 trials: SynKIR™-110 (NCT05568680) in solid tumors and SynKIR™-310 (NCT06544265) in B-cell cancers. Both are investigational.
According to Verismo, early data presented at AACR’s 2026 Annual Meeting showed that SynKIR-110 had a favorable safety profile with dose-dependent efficacy signals and no dose-limiting toxicities. For SynKIR-310, the company reported a complete response in a patient with follicular lymphoma at the lowest dose, sustained beyond six months.
About Verismo Therapeutics
Verismo Therapeutics is a subsidiary of HLB Innovation and develops its multi-chain KIR-CAR platform for advanced solid tumors and B-cell malignancies.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, those statements regarding our expectations for the timing, progress, and results of clinical trials; potential regulatory approvals; anticipated benefits, safety, and efficacy of our product candidates; our product development strategies; and other statements that are not historical facts. These forward-looking statements are based on our current expectations and are subject to numerous risks and uncertainties that could cause actual outcomes to differ materially. Important factors that could cause actual results to differ include, among others, risks related to clinical trials, regulatory processes, market acceptance, financial projections, and our ability to successfully develop and commercialize our product candidates. Forward-looking statements in this release represent our beliefs and assumptions only as of the date hereof, and we expressly disclaim any obligation to update these statements as new information becomes available, except as required by law.
Source: Verismo Therapeutics, https://www.prnewswire.com/news-releases/verismo-therapeutics-licenses-in-vivo-car-t-engineering-technology-to-extend-its-novel-multi-chain-kir-car-platform-302943157.html on November 18, 2026. Republished with credit to the original author. Read the original article.
Investor Relations: Pavel Aprelev, Ph.D. Verismo Therapeutics [email protected]
Media Contact: Peter Collins TogoRun [email protected] 908-499-1200